Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,766,358
  • Shares Outstanding, K 51,440
  • Annual Sales, $ 62,290 K
  • Annual Income, $ -604,190 K
  • 60-Month Beta 0.92
  • Price/Sales 380.81
  • Price/Cash Flow N/A
  • Price/Book 6.11
Trade ARGX with:

Options Overview Details

View History
  • Implied Volatility 43.84%
  • Historical Volatility 35.28%
  • IV Percentile 40%
  • IV Rank 35.37%
  • IV High 56.25% on 01/05/21
  • IV Low 37.04% on 11/20/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 317

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -4.49
  • Number of Estimates 8
  • High Estimate -3.75
  • Low Estimate -5.03
  • Prior Year -3.96
  • Growth Rate Est. (year over year) -13.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
297.03 +0.22%
on 09/28/21
352.89 -15.65%
on 09/03/21
-39.02 (-11.59%)
since 08/27/21
3-Month
291.96 +1.96%
on 07/28/21
352.89 -15.65%
on 09/03/21
-17.56 (-5.57%)
since 06/28/21
52-Week
244.98 +21.51%
on 10/23/20
382.15 -22.11%
on 02/11/21
+42.30 (+16.56%)
since 09/28/20

Most Recent Stories

More News
Avoid These 3 Biotech Stocks That Were Recently Downgraded

The biotech industry is making considerable progress in developing viable drugs and therapies for treating several critical diseases with the integration of advanced technologies. But although rising investments...

GMAB : 42.07 (-2.23%)
ARGX : 297.84 (-2.83%)
XOMA : 25.02 (-1.30%)
Myasthenia Gravis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

The report on Myasthenia Gravis Treatment provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

ARGX : 297.84 (-2.83%)
ALPMF : 16.4800 (-3.43%)
AVDL : 9.81 (-0.91%)
BAX : 80.37 (-0.25%)
GSK : 38.03 (-1.22%)
GRFS : 15.36 (-2.91%)
MTZPY : 18.6000 (-0.13%)
NVS : 82.26 (-0.40%)
RARX : 48.00 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

BIIB : 288.17 (+0.54%)
JNJ : 162.05 (-0.69%)
ALXN : 182.50 (+1.70%)
INCY : 69.13 (-0.19%)
BLUE : 19.65 (+1.66%)
ARGX : 297.84 (-2.83%)
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate....

JNJ : 162.05 (-0.69%)
RHHBY : 44.9600 (-1.43%)
ABBV : 108.01 (+0.27%)
ARGX : 297.84 (-2.83%)
argenx SE to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2021 / argenx SE (NASDAQ:ARGX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 14, 2021 at 8:30 AM Eastern Time....

ARGX : 297.84 (-2.83%)
Myasthenia Gravis Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The report for Myasthenia Gravis Treatment offers an assiduous analysis of contemporary market trends, driving factors, consumer behavior, key player strategies, product usage and brand positioning. The...

ARGX : 297.84 (-2.83%)
ALPMF : 16.4800 (-3.43%)
AVDL : 9.81 (-0.91%)
BAX : 80.37 (-0.25%)
GSK : 38.03 (-1.22%)
GRFS : 15.36 (-2.91%)
MTZPY : 18.6000 (-0.13%)
NVS : 82.26 (-0.40%)
RARX : 48.00 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
argenx SE to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / argenx SE (NASDAQ:ARGX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 2:30 PM Eastern Time....

ARGX : 297.84 (-2.83%)
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

and GHENT, , /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced...

ARGX : 297.84 (-2.83%)
Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises

Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

JNJ : 162.05 (-0.69%)
RHHBY : 44.9600 (-1.43%)
HALO : 39.64 (-1.27%)
ARGX : 297.84 (-2.83%)
argenx SE to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 22, 2020 / argenx SE (NASDAQ:ARGX) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on October 22, 2020 at 2:30 PM Eastern...

ARGX : 297.84 (-2.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

See More

Key Turning Points

3rd Resistance Point 315.96
2nd Resistance Point 312.59
1st Resistance Point 309.54
Last Price 297.84
1st Support Level 303.12
2nd Support Level 299.75
3rd Support Level 296.70

See More

52-Week High 382.15
Fibonacci 61.8% 329.75
Fibonacci 50% 313.57
Last Price 297.84
Fibonacci 38.2% 297.38
52-Week Low 244.98

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar